teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   33 Trials   33 Trials   2608 News 


«12345678910111213...3132»
  • ||||||||||  Journal:  Designing an electrochemical sensor based on ZnO nanoparticle-supported molecularly imprinted polymer for ultra-sensitive and selective detection of sorafenib. (Pubmed Central) -  Oct 24, 2023   
    Also, the imprinting factor (IF) analysis was performed on selected drug substances having structural similarities to SOR and the relative IF values of regorafenib, leflunomide, teriflunomide, nilotinib, axitinib, and dasatinib indicated the selectivity of the developed sensor for SOR...This study is the first electrochemical study for the determination of SOR, and thanks to the ZnO NPs supported MIP sensor, it stands out in terms of both high sensitivity and superior selectivity. Also, this designed sensor provides controlled orientation of the template and complete removal of templates in a one-step process, allowing extremely low detection and quantification limits.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Journal:  The development of multiple sclerosis over the age of 50 (Pubmed Central) -  Oct 9, 2023   
    However, with improved diagnostics and the emergence of new drugs that change the course of MS (disease-modifying therapy), people's life expectancy increases and the percentage of patients in the older age group increases as well. In this article, we consider the possibility of developing MS among people over 50 years of age, features of the course, diagnosis and treatment.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm
    Clinical, Review, Journal:  Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review. (Pubmed Central) -  Oct 9, 2023   
    Briumvi, the fourth type of anti-CD20 antibody was approved by FDA in December 2022, for the treatment of relapsing types of MS, including relapsing-remitting multiple sclerosis, active secondary progressive multiple sclerosis, and clinically isolated syndromes after the drug was tested in two randomized, double-blind, phase III, ULTIMATE I, and II trials which compared Briumvi (ublituximab) with Aubiago (teriflunomide)...The primary mode of action of Briumvi is its high-affinity binding to CD20. Infusion-related reactions are the most common side effects encountered following intravenous administration of ublituximab.
  • ||||||||||  teriflunomide / Generic mfg.
    Enrollment open:  KRONOS: Early Versus Late Ofatumumab (Kesimpta (clinicaltrials.gov) -  Sep 13, 2023   
    P=N/A,  N=100, Recruiting, 
    The special dependency of the patient on glucocorticoids in this study has been rarely reported, which may guide the treatment of insensitivity to disease-modifying therapy in recurrent overlapping anti-NMDAR encephalitis and MS. Not yet recruiting --> Recruiting
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis. (Pubmed Central) -  Sep 11, 2023   
    Dimethyl fumarate (DEFINE) and fingolimod (FREEDOMS I) initially exhibited significant effect on BVL; however, this effect was not confirmed in further clinical trials: CONFIRM and FREEDOMS II, respectively...Our results show that BVL in one of the components of clinical disability worsening, together with other variables (lesion volume and annualized relapse rate). Standardization of atrophy measurement technique as well as harmonization of disability worsening and progression criteria in further clinical trials are of utmost importance as they enable a reliable comparison of neuroprotective potential of DMTs.
  • ||||||||||  dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    P4 data, Retrospective data, Journal:  Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies. (Pubmed Central) -  Sep 7, 2023   
    Standardization of atrophy measurement technique as well as harmonization of disability worsening and progression criteria in further clinical trials are of utmost importance as they enable a reliable comparison of neuroprotective potential of DMTs. Our findings suggest that DMF is associated with a lower risk of relapses than TRF, with more nuanced differences in younger na
  • ||||||||||  dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
    Journal, Real-world evidence, Real-world:  Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis. (Pubmed Central) -  Aug 21, 2023   
    Our study demonstrated no differences in persistence between the actual first-line DMT in a real-world setting, although a trend to favor oral-DMT was seen. Reasons for discontinuation differs within groups.
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Neuropathy in multiple sclerosis patients treated with teriflunomide. (Pubmed Central) -  Aug 20, 2023   
    Teriflunomide has the potential to cause peripheral neuropathy. The awareness of peripheral neuropathy, questioning the symptoms, and if suspected, evaluation with electromyography and switching the therapy in patients under teriflunomide treatment are crucial.
  • ||||||||||  Vumerity (diroximel fumarate) / Biogen
    Trial completion date, Trial initiation date, Trial primary completion date:  A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) (clinicaltrials.gov) -  Aug 18, 2023   
    P=N/A,  N=10500, Not yet recruiting, 
    The awareness of peripheral neuropathy, questioning the symptoms, and if suspected, evaluation with electromyography and switching the therapy in patients under teriflunomide treatment are crucial. Trial completion date: Feb 2028 --> Dec 2032 | Initiation date: Jun 2023 --> Dec 2023 | Trial primary completion date: Feb 2028 --> Dec 2032
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Trial completion date, Trial primary completion date:  DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov) -  Aug 16, 2023   
    P4,  N=800, Recruiting, 
    Trial completion date: Feb 2028 --> Dec 2032 | Initiation date: Jun 2023 --> Dec 2023 | Trial primary completion date: Feb 2028 --> Dec 2032 Trial completion date: Sep 2026 --> Sep 2030 | Trial primary completion date: Dec 2025 --> Apr 2030
  • ||||||||||  teriflunomide / Generic mfg.
    P3 data, Review, Journal:  Is it ethical to use teriflunomide as an active comparator in phase 3 trials? (Pubmed Central) -  Aug 15, 2023   
    An online survey indicates that the majority of the MS community feels it is still ethical to randomise subjects to teriflunomide and that procedures can be put in place to protect trial subjects randomised to teriflunomide. Therefore, we still have equipoise, and teriflunomide comparator trials are ethical.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    Trial completion date, Trial primary completion date:  STHENOS: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (clinicaltrials.gov) -  Aug 8, 2023   
    P3,  N=186, Recruiting, 
    The proposed calculation method based on topological indices is fast, easy to use and avoids valuable and lengthy laboratory experiments required in the case of experimental ADME/T studies. Trial completion date: Feb 2025 --> Sep 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Teriflunomide treatment outcomes in multiple sclerosis: A Portuguese real-life experience. (Pubmed Central) -  Jul 26, 2023   
    TeriLIVE-QoL provides real-world evidence of clinical effectiveness, high treatment satisfaction, consistent safety and improved psychiatric outcomes, associated with elevated treatment persistence and compliance in patients treated with teriflunomide.iance reached 82% 2 years after initiation. Three patients experienced serious adverse events.
  • ||||||||||  teriflunomide / Generic mfg.
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  ULTIMS: Ultra-high-field Brain MRI in Multiple Sclerosis (clinicaltrials.gov) -  Jul 6, 2023   
    P=N/A,  N=10, Recruiting, 
    These estimates should be useful for interpreting scores and communicating study results and should facilitate decision-making by regulatory and healthcare authorities where these 8 PROs are commonly employed. Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Mar 2024 | Initiation date: Mar 2023 --> Jun 2023 | Trial primary completion date: Dec 2023 --> Mar 2024
  • ||||||||||  teriflunomide / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  An Observational Study on Teriflunomide-exposed Pregnancies (clinicaltrials.gov) -  Jul 6, 2023   
    P=N/A,  N=220, Completed, 
    Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Mar 2024 | Initiation date: Mar 2023 --> Jun 2023 | Trial primary completion date: Dec 2023 --> Mar 2024 Recruiting --> Completed | N=325 --> 220 | Trial completion date: Jul 2023 --> Apr 2023 | Trial primary completion date: Jul 2023 --> Apr 2023
  • ||||||||||  teriflunomide / Generic mfg.
    Review, Journal:  Teriflunomide: an oral therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis. (Pubmed Central) -  Jun 29, 2023   
    Despite the potential benefits of teriflunomide, changes in clinical practice may be hindered by factors such as cost and physician familiarity with alternative treatments. Longer-term studies and biomarker identification are areas for improvement, but the future of research in this area holds promise for the continued development and refinement of disease-modifying therapies and more personalized, targeted treatments for pediatric MS patients.
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis. (Pubmed Central) -  Jun 19, 2023   
    Longer-term studies and biomarker identification are areas for improvement, but the future of research in this area holds promise for the continued development and refinement of disease-modifying therapies and more personalized, targeted treatments for pediatric MS patients. TER promotes the tolerogenic immune response and suppresses the pathogenic immune response in patients with RRMS.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Briumvi (ublituximab) / TG Therap
    FDA event, Journal:  Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis. (Pubmed Central) -  Jun 19, 2023   
    Here, we discuss the main findings obtained during the phase 3 clinical trials (ULTIMATE I and II) for ublituximab versus teriflunomide. The current emergence and approval of new anti-CD20 mAbs with different dose regimens, routes of application, glycoengineering and mechanisms of action may contribute to different clinical outcomes.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech
    Journal:  Three to four mRNA COVID-19 vaccine in multiple sclerosis patients on immunosuppressive drugs: seroconversion and variants neutralization. (Pubmed Central) -  Jun 13, 2023   
    The current emergence and approval of new anti-CD20 mAbs with different dose regimens, routes of application, glycoengineering and mechanisms of action may contribute to different clinical outcomes. In MS patients on anti-CD20, an enhanced primary vaccination scheme moderately increased anti-RBD seropositivity and anti-RBD antibody titer, but neutralization activity remained modest even after a 4 booster injection.
  • ||||||||||  azacitidine / Generic mfg.
    Journal:  Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol. (Pubmed Central) -  Jun 10, 2023   
    Cells administered AZA treatment can switch to de novo synthesis of pyrimidine nucleotides, which could be blocked by inhibition of dihydroorotate dehydrogenase by teriflunomide (TFN). This is shown by the synergistic effect of AZA and TFN in those variants that were cross-resistant to DAC and did not have a mutation in UCK2.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota. (Pubmed Central) -  Jun 5, 2023   
    However, the association between DMTs exposure and microbial changes was mostly indirect, and the results of the different studies needed to be more consistent. The mitigation of methodological bias is necessary for future studies to allow the identification of a "microbial signature" related to MS pathophysiology, the role of DMTs, and possible prognostic implications.
  • ||||||||||  Vumerity (diroximel fumarate) / Biogen, Ponvory (ponesimod) / J&J
    Journal:  Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis. (Pubmed Central) -  May 29, 2023   
    P3
    We did not observe differences between DRF and PON for ARR, CDP, and absence of new/newly enlarging T2 lesions, but there was a higher proportion of patients free of Gd+ T1 lesions among DRF-treated patients than PON-treated patients. DRF had improved efficacy versus TERI for all clinical and radiological outcomes, except for absence of new/newly enlarging T2 lesions.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Review, Journal:  Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis. (Pubmed Central) -  May 29, 2023   
    All the DMTs approved to date target immunomodulation as their mechanism of action (MOA); however, the direct effects of some DMTs on the central nervous system (CNS), particularly sphingosine 1-phosphate (S1P) receptor (S1PR) modulators, implicate a parallel MOA that may also reduce neurodegenerative sequelae. This review summarizes the currently approved DMTs for the treatment of MS and provides details and recent advances in the molecular pharmacology, immunopharmacology, and neuropharmacology of S1PR modulators, with a special focus on the CNS-oriented, astrocyte-centric MOA of fingolimod.